Inotiv, Inc.

    Inotiv, Inc.

    NNASDAQ:NOTV
    0.01
    USD
    +0.00
    (-19.41%)
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    2025 Y
    TTM
    Revenue per Share
    2.88
    3.09
    2.81
    2.52
    2.96
    3
    4.2
    5.57
    6.79
    22.49
    22.32
    18.95
    15.81
    14.73
    Basic EPS, GAAP
    0.1
    -0.13
    0.14
    -0.4
    0.11
    -0.02
    -0.08
    -0.43
    0.83
    -13.84
    -4.1
    -4.19
    -2.11
    -2.53
    Free Cash Flow per Basic Share
    0.21
    0.21
    0.26
    0.13
    0.15
    0.4
    0.17
    0.12
    0.81
    -0.21
    1.09
    -0.26
    -0.32
    0.01
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    1.05
    1.03
    1.18
    0.77
    0.9
    1.06
    1.02
    0.69
    6.6
    14.08
    10.44
    6.55
    3.96
    2.21
    Tangible Book Value per Share
    0.88
    0.91
    1.05
    0.77
    0.9
    0.44
    0.4
    -0.1
    1.82
    -5.6
    -5.18
    -7.62
    -5.78
    -6.87
    Basic Weighted Avg Shares
    8
    8
    8
    8
    8
    9
    10
    11
    13
    24
    26
    26
    32
    34
    Sales/Revenue/Turnover
    22
    25
    23
    20
    24
    26
    44
    60
    90
    548
    572
    491
    513
    507
    Operating Margin (%)
    3.76
    2.88
    1.34
    -10.12
    5.27
    0.05
    -0.35
    -5.07
    -0.27
    3.7
    -1.61
    -11.1
    -7.21
    -8.97
    Depreciation Expense
    2
    2
    1
    2
    2
    2
    3
    4
    6
    49
    55
    57
    56
    56
    Net Income, GAAP
    1
    -1
    1
    -3
    1
    - -
    -1
    -5
    11
    -337
    -105
    -108
    -69
    -87
    Effective Tax Rate (%)
    2.03
    - -
    1.35
    - -
    2.64
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    3.5
    -4.35
    4.84
    -15.8
    3.65
    -0.74
    -1.81
    -7.75
    12.16
    -61.54
    -18.37
    -22.1
    -13.38
    -17.14
    Working Capital
    -4
    -3
    -3
    -9
    -2
    -4
    -5
    -16
    134
    69
    82
    44
    -362
    -396
    LT Debt
    5
    5
    4
    - -
    4
    9
    14
    22
    161
    356
    399
    430
    47
    57
    Total Equity
    9
    10
    11
    7
    8
    11
    11
    8
    105
    360
    268
    171
    136
    77
    Return on Invested Capital (%)
    4.86
    - -
    1.96
    - -
    10.86
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    8.39
    - -
    8.88
    - -
    9.67
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    10.19
    -12.99
    12.28
    -40.84
    12.9
    -2.12
    -7.34
    -51.35
    19.33
    -144.8
    -33.4
    -49.33
    -44.78
    -74.09

    Capital Structure

    USD

    •

    in mil. unless spec.
    Sep'25
    Dec'26
    Mar'26
    ST Debt
    413
    418
    430
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    47
    58
    57
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    34
    34
    35
    Market Capitalization
    50
    19
    10

    Working Capital

    USD

    •

    in mil. unless spec.
    Sep'25
    Dec'26
    Mar'26
    Total Current Assets
    195
    164
    144
    Cash, Cash Equivalents & STI
    22
    13
    15
    Accounts Receivable, Net
    74
    59
    58
    Inventories
    46
    44
    31
    Total Current Liabilities
    557
    539
    540
    Payables & Accruals
    72
    66
    50
    ST Debt
    413
    418
    430
    Deferred Revenue
    52
    37
    38

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    142.5%
    288.82%
    -20.22%
    Free Cash Flow
    -4.81%
    -24.15%
    53.64%
    Net Income, GAAP
    -347.12%
    -725.65%
    -36.72%
    Sales/Revenue/Turnover
    67.57%
    110.83%
    4.54%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    136
    119
    106
    130
    491
    2025
    120
    124
    131
    138
    513
    2026
    121
    118
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    -0.6
    -1.86
    -1
    -0.73
    -4.19
    2025
    -1.02
    -0.44
    -0.51
    -0.25
    -2.11
    2026
    -0.83
    -0.94
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • businesswire.com

      Inotiv Successfully Completes Financial Restructuring Process

    • businesswire.com

      Inotiv Announces Confirmation of Plan of Reorganization

    • businesswire.com

      Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

    • globenewswire.com

      Inotiv Provides Notice Regarding Cybersecurity Incident

    • seekingalpha.com

      Inotiv, Inc. (NOTV) Q1 2026 Earnings Call Transcript

    • globenewswire.com

      Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

    • globenewswire.com

      Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026

    • defenseworld.net

      Ernexa Therapeutics (NASDAQ:ERNA) vs. Inotiv (NASDAQ:NOTV) Critical Review

    • globenewswire.com

      Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery

    • globenewswire.com

      Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

    • seekingalpha.com

      Inotiv, Inc. (NOTV) Q4 2025 Earnings Call Transcript

    • globenewswire.com

      Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update

    • globenewswire.com

      Inotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™

    • globenewswire.com

      Inotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025

    • globenewswire.com

      Inotiv, Inc. Announces Preliminary Fiscal 2025 Fourth Quarter and Full Year Results

    • businesswire.com

      Halper Sadeh LLC Encourages Inotiv, Inc. Shareholders to Contact the Firm to Discuss Their Rights

    • globenewswire.com

      Inotiv, Inc. to Participate in Three Investor Conferences in September 2025

    • seekingalpha.com

      Inotiv, Inc. (NOTV) Q3 2025 Earnings Call Transcript

    • globenewswire.com

      CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update

    • zacks.com

      Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates